drugset
drugset / Trial / NCT01760642

Identification and Evaluation of Endogenous Markers for the Assessment of CYP3A Activity

NCT01760642 ↗

Phase 1 Completed 16 enrolled Seoul National University Hospital
NaSingle-groupOpen-labelTreatment

Summary

Identification and evaluation of endogenous markers for the assessment of CYP3A activity in female subjects using metabolomics

Timeline

Start
2012-12
Primary completion
2013-09
Completion
2013-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule 400 mg Oral
Subject Midazolam Small molecule 3 mg Intravenous
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.